A modified histochemical method was used to show the presence of dipeptidyl aminopeptidase (DAP) II and IV in fixed, freeze dried, cryostat sections of tonsils, lymph nodes, and skin. In 14 reactive tonsils and lymph nodes both enzyme reactions were largely confined to T dependent areas where scattered positive lymphocytes were shown in the paracortical zones, while lymphocytes of germinal centres (B dependent areas) were negative. In either site some macrophages showed strong positivity for both enzymes. In 23 lymph node and two skin biopsy specimens of non-Hodgkin's lymphoma the neoplastic lymphocytes of 12 B cell lymphomas were completely unstained, whereas in the 13 cases of T cell lymphoma the neoplastic lymphocytes showed variable reactions with positivity for DAP II in eight and for DAP IV in seven, both reactions being positive in four and negative in two. Touch imprints of a lymph node from a case of Hodgkin's disease showed that the Reed-Sternberg cells were unreactive for both enzymes. The histochemistry of DAP II and IV may supplement other histochemical and immunological markers in the cytological classification of lymphomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1141007 | PMC |
| http://dx.doi.org/10.1136/jcp.40.5.480 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two-year follow-up of gait and postural control following initiation of recombinant human tripeptidyl intracerebroventricular enzyme replacement therapy in two atypical CLN2 patients.
Sci Rep
January 2025
Division of Metabolic Disorders, CHOC Children's Hospital, Orange, CA, 92868, USA.
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder leading to premature mortality. Ambulatory CLN2 patients typically receive standard of care treatment through biweekly intracerebroventricular (ICV) enzyme replacement therapy (ERT) involving recombinant human tripeptidyl peptidase 1, known as cerliponase alfa (Brineura, Biomarin Pharmaceuticals). This study longitudinally assessed the impact of ICV cerliponase alfa ERT on gait, and postural control across a two-year span in two siblings diagnosed with atypical CLN2 disease.
View Article and Find Full Text PDFBioinformatic characterization of ENPEP, the gene encoding a potential cofactor for SARS-CoV-2 infection.
PLoS One
December 2024
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Research on SARS-CoV-2, the viral pathogen that causes COVID-19, has identified angiotensin converting enzyme 2 (ACE2) as the primary viral receptor. Several genes that encode viral cofactors, such as TMPRSS2, NRP1, CTSL, and possibly KIM1, have since been discovered. Glutamyl aminopeptidase (APA), encoded by the gene ENPEP, is another cofactor candidate due to similarities in its biological role and high correlation with ACE2 and other human coronavirus receptors, such as aminopeptidase N (APN) and dipeptidyl peptidase 4 (DPP4).
View Article and Find Full Text PDFCerliponase alfa decreases Aβ load and alters autophagy- related pathways in mouse hippocampal neurons exposed to fAβ.
Life Sci
November 2024
Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Sihhiye, Ankara, Turkiye. Electronic address:
Article Synopsis
- Extracellular aggregation of amyloid-beta (Aβ) in the brain is linked to Alzheimer's disease (AD), and its intraneuronal accumulation may also contribute to disease progression.
- The study investigates the effect of tripeptidyl peptidase-1 (TPP1), a lysosomal enzyme, and its recombinant form (cerliponase alfa) in reducing Aβ levels within neuron cells while examining the role of autophagy.
- Results showed that cerliponase alfa decreased Aβ accumulation and triggered autophagy-related pathways, suggesting TPP1 enhancement might be a potential Alzheimer’s therapy.
Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab.
Life Sci Alliance
December 2024
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama, Japan
Article Synopsis
- - The amyloid β peptide (Aβ3pE-42), linked to Alzheimer's disease, is known to accumulate in the brain, and a therapeutic antibody called donanemab has shown promise in clinical trials for treating it.
- - Research indicates that Aβ3pE-42 is more stable than other variants and its accumulation is influenced by a deficiency in neprilysin, an enzyme that typically breaks down Aβ, which leads to its selective deposition in mouse models.
- - The study suggests that treatments targeting Aβ3pE-42 may be more successful if administered prior to its accumulation in the brain, highlighting the importance of timing in anti-Aβ therapies.
Aminopeptidasic Enzymes as Early Biomarkers of Cardiac Surgery-Associated Acute Kidney Injury and Long-Term Events.
Biomolecules
August 2024
Area of Physiology, Department of Health Sciences, University of Jaén, 23071 Jaén, Spain.
Background: Diagnosis of acute kidney injury (AKI) relies on serum creatinine (SCr) changes. This study investigated if urinary aminopeptidases are early and predictive biomarkers of cardiac surgery-associated AKI (CSA-AKI).
Methods: Glutamyl aminopeptidase (GluAp), alanyl aminopeptidase (AlaAp), dipeptidyl peptidase-4 (DPP4), proteinuria, albuminuria, N-acetyl-β--glucosaminidase (NAG), and neutrophile gelatinase-associated lipocalin (NGAL) were measured in urine samples from 44 patients at arrival in the intensive care unit (ICU) after cardiac surgery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!